205 related articles for article (PubMed ID: 25268733)
1. 5-Alpha-reductase inhibitors in diseases of the prostate.
Carrasquillo RJ; Nealy SW; Wang DS
Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):488-92. PubMed ID: 25268733
[TBL] [Abstract][Full Text] [Related]
2. 5-Alpha reductase inhibitors in active surveillance.
Richard PO; Finelli A
Curr Opin Urol; 2014 May; 24(3):324-8. PubMed ID: 24710052
[TBL] [Abstract][Full Text] [Related]
3. The role of 5-alpha-reductase inhibitors in active surveillance.
Margel D; Fleshner N
Curr Opin Urol; 2012 May; 22(3):243-6. PubMed ID: 22472511
[TBL] [Abstract][Full Text] [Related]
4. Dutasteride for the treatment of prostate-related conditions.
Slater S; Dumas C; Bubley G
Expert Opin Drug Saf; 2012 Mar; 11(2):325-30. PubMed ID: 22316171
[TBL] [Abstract][Full Text] [Related]
5. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
[TBL] [Abstract][Full Text] [Related]
6. Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer.
Schmidt LJ; Tindall DJ
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):32-8. PubMed ID: 20883781
[TBL] [Abstract][Full Text] [Related]
7. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
Morlock R; Goodwin B; Gomez Rey G; Eaddy M
Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
[TBL] [Abstract][Full Text] [Related]
8. Hormonal manipulation of benign prostatic hyperplasia.
Rick FG; Saadat SH; Szalontay L; Block NL; Kazzazi A; Djavan B; Schally AV
Curr Opin Urol; 2013 Jan; 23(1):17-24. PubMed ID: 23202285
[TBL] [Abstract][Full Text] [Related]
9. [Opportunities and risks of 5α reductase inhibitors in the medical management of Active surveillance for localized prostate cancer].
Linares Espinos E; Carballido Rodriguez J
Arch Esp Urol; 2014 Jun; 67(5):457-61. PubMed ID: 24914845
[TBL] [Abstract][Full Text] [Related]
10. [REVIEW OF CLINICAL STUDIES ON COMBINATION THERAPY OF 5α-REDUCTASE INHIBITORS AND α1-BLOCKERS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA].
Spivak LG; Lokshin KL; Vinarov AZ
Urologiia; 2015; (4):125-33. PubMed ID: 26665780
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer prevention with 5-alpha reductase inhibitors: concepts and controversies.
Liss MA; Thompson IM
Curr Opin Urol; 2018 Jan; 28(1):42-45. PubMed ID: 29095730
[TBL] [Abstract][Full Text] [Related]
12. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
[TBL] [Abstract][Full Text] [Related]
13. The clinical applications of five-alpha reductase inhibitors.
Loughlin KR
Can J Urol; 2021 Apr; 28(2):10584-10588. PubMed ID: 33872554
[TBL] [Abstract][Full Text] [Related]
14. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.
Oelke M; Bachmann A; Descazeaud A; Emberton M; Gravas S; Michel MC; N'dow J; Nordling J; de la Rosette JJ;
Eur Urol; 2013 Jul; 64(1):118-40. PubMed ID: 23541338
[TBL] [Abstract][Full Text] [Related]
15. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
[TBL] [Abstract][Full Text] [Related]
16. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
Rittmaster RS
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
[TBL] [Abstract][Full Text] [Related]
17. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
[TBL] [Abstract][Full Text] [Related]
18. Dutasteride for the treatment of benign prostatic hyperplasia.
Wu C; Kapoor A
Expert Opin Pharmacother; 2013 Jul; 14(10):1399-408. PubMed ID: 23750593
[TBL] [Abstract][Full Text] [Related]
19. Biology and natural history of prostate cancer and the role of chemoprevention.
Rosenberg MT; Froehner M; Albala D; Miner MM
Int J Clin Pract; 2010 Dec; 64(13):1746-53. PubMed ID: 21070525
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology for common urologic diseases: 2011 review for the primary care physician.
Liu XS; Folia C; Gomella LG
Can J Urol; 2011 Apr; 18 Suppl():24-38. PubMed ID: 21501548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
